BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 11555612)

  • 1. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
    Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y; Kyprianou N
    Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
    Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
    Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
    Ko Y; Banerji SS; Liu Y; Li W; Liang J; Soule HD; Pauley RJ; Willson JK; Zborowska E; Brattain MG
    J Cell Physiol; 1998 Aug; 176(2):424-34. PubMed ID: 9648930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
    FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M; Oyasu R
    Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
    Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X; Bellis S; Yan Z; Friedman E
    Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
    Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma.
    Löhr M; Schmidt C; Ringel J; Kluth M; Müller P; Nizze H; Jesnowski R
    Cancer Res; 2001 Jan; 61(2):550-5. PubMed ID: 11212248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
    Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
    Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
    Zhou R; Xiong B; Song H; Liu S; Wang X
    Oncol Rep; 2008 Dec; 20(6):1449-56. PubMed ID: 19020727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
    Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
    Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.